{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreihov7igexnhfr7k3djzri2sxglqpvmsl2azn7jra4dsw47g2ss27y",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mnmlj7txsa72"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreia65xrhqxnp4lv2cnvp6cuhvdzq7s2aehkxx6gaikbcupybdqrowm"
    },
    "mimeType": "image/jpeg",
    "size": 74628
  },
  "path": "/2026/06/05/biotech-news-will-makarys-fda-voucher-program-survive/?utm_campaign=rss",
  "publishedAt": "2026-06-05T13:45:12.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Biotech",
    "Business",
    "Pharma",
    "The Readout",
    "biotechnology",
    "drug development",
    "Drug prices",
    "research"
  ],
  "textContent": "RevMed's cancer drug feels out of reach for some, SCOTUS preserves key generic drug pathway, and more biotech news",
  "title": "STAT+: Will Makary’s FDA voucher program survive?",
  "updatedAt": "2026-06-05T13:45:17.000Z"
}